Retatrutide 50mg – 10 vials

Retatrutide (also referred to as LY3437943) is a novel triple incretin receptor agonist that simultaneously targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This tri-agonist mechanism distinguishes it from dual or single receptor agonists, making it a subject of considerable interest in metabolic and obesity-related research.

By co-activating all three receptor pathways, retatrutide is investigated for its potential to modulate appetite regulation, enhance energy expenditure, improve glycaemic control, and reduce adiposity. Preclinical and early clinical research has explored its superior efficacy in weight reduction compared to single or dual agonists, with studies suggesting pronounced effects on body weight and metabolic markers.

Retatrutide has demonstrated research relevance across areas including type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD/NASH), and cardiometabolic syndrome. Its multi-receptor activity offers researchers a valuable tool for dissecting incretin biology and evaluating downstream metabolic outcomes.

Specifications: Molecular Formula: C₂₂₄H₃₅₆N₅₈O₇₂ | Molecular Weight: ~4963.5 g/mol | Purity: >98% | CAS Number: 2381272-06-4 | Form: Lyophilised Powder.

Storage: Store at -20°C. Protect from light and moisture. Stable for up to 24 months when stored correctly.

For research purposes only. Not for human use.